Deborah Minor

Early development is centered on the science: proving the concept, advancing preclinical work, preparing for funding milestones, and moving toward clinical development. While these priorities are critical, Chemistry, Manufacturing, and Controls can quickly become one of the most important factors influencing whether a program advances smoothly or encounters costly delays. At Drug Discovery Alliances, we see that CMC decisions made early in development can have long-term implications for...

Innovation in pharmaceutical development rarely happens in isolation. As scientific complexity increases and development timelines become more demanding, collaboration across biotech companies, academic institutions, and large pharmaceutical organizations has become one of the most effective ways to advance programs from discovery to commercialization. Strategic alliances are helping companies move faster, reduce risk, and access specialized expertise that may not exist internally. From...

In drug development, the difference between a program that advances on schedule and one that stalls rarely comes down to the science. More often, it comes down to whether the right expertise was available at the right moment. For emerging biotech and biopharma companies, that expertise is frequently absent precisely when it is needed most: at the inflection points where CMC strategy, regulatory documentation, and manufacturing execution demand senior-level leadership. Drug Discovery Alliances...